NCT01243762 2018-08-16A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)Merck Sharp & Dohme LLCPhase 1 Terminated47 enrolled 12 charts
NCT00818675 2015-01-21A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)Merck Sharp & Dohme LLCPhase 2 Terminated80 enrolled